Genesys Capital to earn up to 15x its investment on sale of Naurex
Life sciences venture firm Genesys Capital, which has recently tied up a number of lucrative exits, will chalk up another with the proposed sale of a U.S. antidepressant drug maker. This week, Allergan said it would spend US$560 million upfront to acquire Naurex. The deal promises to give the Toronto-based Genesys as much as 15 times its invested capital.
31 July 2015•3 mins read
